Log In
BCIQ
Print this Print this
 

anti-VEGF/Ang2 Nanobody (BI 836880)

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionBispecific Nanobody targeting VEGF and angiopoietin 2 (ANG2; ANGPT2)
Molecular Target Vascular endothelial growth factor (VEGF) ; Angiopoietin 2 (ANG2) (ANGPT2)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerBoehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today